Avricore Health Reports Second-Quarter 2022 Results

Avricore Health Reports Second-Quarter 2022 Results

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's Q2 results.

"We have now begun a new era for Healthtab™ and the Company as we expand Shoppers Drug Mart significantly over the coming weeks," said Hector Bremner, CEO of Avricore Health Inc. "We are now realizing our revenue targets and are on track to realize long-term profitability as we continue to successfully execute our plan."

HEALTHTAB™ – KEY DEVELOPMENTS

Key developments have included:

  • The Company is significantly expanding the number of Shoppers Drug Mart® pharmacies offering its Healthtab™ point-of-care testing platform under a renewed Master Service Agreement (MSA) to up to 450 locations nation-wide.

  • In addition to Shoppers Drug Mart® pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize Healthtab™ upon request.

  • As of the date of this report 103 participating Shoppers Drug Mart® pharmacies, 84 in Ontario and 14 in British Columbia, 4 in Nova Scotia and 1 in New Brunswick have now received their HealthTab™ systems and are offering screening tests to patients.

  • Additionally, the Company was honoured to have Healthtab™ placed in the first pharmacist-led primary healthcare clinic located in Lethbridge, Alberta. Not only was this the first clinic, it was also the first system placed in a Real Canadian Superstore®, as well as its first Alberta location.

  • As of July 1 st , 2022, the Government of Ontario brought into effect an expanded scope of practice for community pharmacists in the province, joining Alberta in this growing and popular approach.

  • Shoppers Drug Mart® pilot data was recently released in August via the Ontario Pharmacists Association showing over 15,000 Healthtab™ tests were completed for more than 6,900 patients.  The data collected confirmed that the patients tested had a high prevalence of previously undiagnosed diabetes, pre-diabetes and heart disease and significant near-term risk for major health events. Almost 60 per cent of patients needed an intervention to better manage their chronic disease. On average, 31 percent received a new chronic medication, 28 percent required a change in their current medication, and 235 patients were newly identified as diabetic. Patients also reported in post surveys that they valued receiving this information from their pharmacists, and those pharmacists indicated that Healthtab™ enabled an increase in the value of services they were able to provide to their patients.

  • Developed a quality assurance program with a third-part reference laboratory to offer HealthTab pharmacies industry leading validation for point-of-care instruments and test consumables.

  • Developing new pilot programs with national pharmacy chains,

  • Continuing to negotiate new POC service integrations to expand the HealthTab™ testing menu.

  • Refining HealthTab™'s de-centralized clinical trials capabilities to monetize de-identified data associated with high-value Real-World Evaluation (RWE).

  • Moving forward with negotiations across several target demographics, domestically and internationally, with life-science companies, host-locations and Clinical Research Organizations (CRO).

QUARTERLY FINANCIAL INFORMATION

The following table highlights selected unaudited consolidated financial data for each of the eight most recent quarters that, in management's opinion, have been prepared on a basis consistent with the audited consolidated financial statements for the year ended December 31, 2021. These results are not necessarily indicative of results for any future period and you should not rely on these results to predict future performance.

Quarter Ended Jun
2022
Mar
2022
Dec
2021
Sep
2021
Jun
2021
Mar
2021
Dec
2020
Sep
2020
$ $ $ $ $ $ $ $
Revenue 176,175 42,736 35,190 75,104 4,939 7,575 8,082 8,082
Gross profit (loss) 56,874 15,113 9,317 20,555 (998 ) 1,647 2,220 4,757
Share-based
compensation
9,069 21,099 9,169 74,722 24,965 386,935 120,191 10,028
Comprehensive Loss 207,363 185,678 208,895 439,311 344,620 715,306 538,499 206,789
Net loss/Share (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.00 ) (0.01 ) (0.00 ) (0.00 )
Total Assets 1,985,085 2,122,816 2,281,393 2,517,569 2,541,099 2,740,053 440,090 355,808

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2022

The Company incurred comprehensive loss of $207,363 for the three months ended June 30, 2022 (2021 - $344,620) a decrease of 40%.

Significant changes are as follows:

  • Revenue increased to $176,175 (2021 - $4,939) due to an increase in HealthTab™ systems deployed and tests sold. Gross profit amounted to $56,874 (2021 – negative gross profit of $998).

  • Expenses decreased to $266,739 (2021 – $343,716) a decrease of 22%, primarily due to a decrease in consulting and shareholder communications costs.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

About HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

HealthTab™ Market Fast Facts

  • Point of Care Testing Market to reach $93.21 Billion USD in 2030 ( Source )
  • Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed ( Source )
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source )
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. ( Source )
  • There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

Contact :

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCR:CA
The Conversation (0)
Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of the year previous and have great momentum for 2024.

"Patients and pharmacists are discovering and accessing new information that's having a powerful impact on their care and support thanks to HealthTab," said Hector Bremner, CEO of Avricore Health Inc. "Our ambition of helping more people live better is becoming reality each day and we are poised to make big breakthroughs in bringing this service to more patients around the world."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, HealthTab™, further into the Canadian pharmacy ecosystem with one of Canada's largest pharmacy retailers, Rexall Pharmacy Group ULC ("Rexall").

"With Pharmacies' expanded scope and rising patient demand, the need for the clinical pharmacy practice is greater than ever," said Hector Bremner, CEO of Avricore Health. "We're excited to work with Rexall pharmacy teams to support positive patient outcomes through real-time insights into their health."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world.

"We've had an incredible year so far and we're very excited about what's still to come," said Hector Bremner, CEO of Avricore Health Inc. "Make no mistake, with new partners in Canada and expansion into the UK, we have nothing but blue sky in front of us."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a reseller agreement between HealthTab™ Inc. and Abbott Rapid Dx UK & Ireland.

This agreement provides a foundation for HealthTab to purchase and distribute the Afinion™ 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased that HealthTab, the Company's leading pharmacy-based platform for testing and health data management, has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

"In the wake of the pandemic, it's clear that the community pharmacy needs to play a bigger role in delivering more access to healthcare services, especially chronic disease screening and management," said Hector Bremner, CEO of Avricore Health. "We are honoured to have been selected for this important project and look forward to working with pharmacist as they support patients with this vital service."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sona Nanotech Grants Options

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that that it has granted 1,195,000 incentive stock options under the Company's Stock Option Plan ("Option Plan"), of which 810,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.31 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.

Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Ocumetics Technology Corp  To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

Ocumetics Technology Corp To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - February 29, 2024 - Ocumetics Technology Corp. ("Ocumetics") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
ARway.ai The Spatial Computing Company To Present at the Emerging Growth Conference March 7

ARway.ai The Spatial Computing Company To Present at the Emerging Growth Conference March 7

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce that it has been invited to present at the Emerging Growth Conference on March 7, 2024

ARway.ai invites individual and institutional investors as well as advisors and analysts, to attend the real-time, interactive presentation at the Emerging Growth Conference.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
XReality Group

Appendix 4D and Half Year Financial Report

xReality Group Limited (ASX:XRG) is pleased to present its Half Year Report.

Keep reading...Show less
ARway.ai The Spatial Computing Company Signs New Deal With Kuwait Agency For AR Navigation

ARway.ai The Spatial Computing Company Signs New Deal With Kuwait Agency For AR Navigation

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce a new deal with AMANAH TEKNOLOGIA, located in Kuwait City, Kuwait. They are another ARway.ai partner, leading technology company and system integrator that provides innovative products to enhance the way businesses and people interact with technology; software development, cloud hosting, e-commerce and marketing

This deal encompasses a project to prototype mobile application for hospitals that integrates with EMR systems and acts as a digital concierge for visitors and staff. The prototype will be tested at the Dar AlShifa Hospital in Kuwait, which will leverage the ARwayKit SDK to provide AR navigation and immersive educational experiences throughout the entire facility. This ensures the hospital journey is as easy and seamless as possible.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
ARway.ai Expanding Its Spatial Computing Platform, Hires New AI Computer Vision and Machine Learning Ph.D Engineer

ARway.ai Expanding Its Spatial Computing Platform, Hires New AI Computer Vision and Machine Learning Ph.D Engineer

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is excited to announce Soumic Sarkar as a new Computer Vision and Machine Learning Engineer to its existing team bringing its total AI team to eleven as it ramps up its spatial computing platforms capabilities. With a distinguished background in robotics and machine learning, Mr. Sarkar brings a wealth of experience from prestigious institutions and leading-edge projects

With an academic foundation holding a Ph.D. in Control and Automation from the Indian Institute of Technology Delhi, and a rich professional history that includes contributions to robotic navigation, sensor fusion, and autonomous systems design, Mr. Sarkar's expertise is set to propel ARway.ai's spatial computing platform to new heights.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×